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ARTICLE
Hypoxia Inducible Factor 1: A Urinary Biomarker of Kidney
Disease
S Movafagh1,∗, D Raj2, M Sanaei-Ardekani3, D Bhatia1, K Vo4, M Mahmoudieh4, R Rahman3, EH Kim3 and AF Harralson1
Identifying noninvasive biomarkers of kidney disease is valuable for diagnostic and therapeutic purposes.
Hypoxia inducible factor 1 (HIF-1) expression is known to be elevated in the kidneys in several renal dis-
ease pathologies. We hypothesized that the urinary HIF-1a mRNA level may be a suitable biomarker for
expression of this protein in chronic kidney disease (CKD). We compared HIF-1a mRNA levels from urine
pellets of CKD and healthy subjects. To ensure that urinary HIF-1a mRNA is of kidney origin, we exam-
ined colocalization of HIF-1a mRNA with two kidney specific markers in urine cells. We found that HIF-1a
mRNA is readily quantifiable in urine pellets and its expression was significantly higher in CKD patients
compared with healthy adults. We also showed that the urinary HIF-1a mRNA comes primarily from cells
of renal origin. Our data suggest that urinary HIF-1a mRNA is a potential biomarker in CKD and can be
noninvasively assessed in patients.
Clin Transl Sci (2017) 00, 1–7; doi:10.1111/cts.12445; published online on YYYY-MM-DD.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Currently, evidence suggests a close relationship
between hypoxic signaling via HIF-1 and pathogenesis of
CKD. However, no biomarkers have yet been identified to
noninvasively assess HIF-1a expression levels in patient
kidneys.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ This study addresses the feasibility and validity of using
urinary HIF-1a mRNA levels as a noninvasive biomarker of
kidney HIF-1a expression levels.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE?
✔ The study shows that urinary HIF-1a mRNA is read-
ily measurable in urine and is significantly elevated by
3.91-fold in patients with stage 3–5 CKD compared with
healthy adults. Together, these findings suggest that urinary
HIF-1a mRNA index could be utilized as a biomarker for
HIF-1a levels in the kidneys in CKD.
HOW THIS MIGHT CHANGE CLINICAL
PHARMACOLOGY OR TRANSLATIONAL SCIENCE
✔ Using HIF-1amRNA levels in urine can guide and assess
the effectiveness of HIF-1-modulating therapies currently
in development in treatment of CKD and other renal
pathologies.
Among many factors that precipitate kidney failure, hypoxia
appears to be a critical underlying feature. Histological
samples of diseased kidneys show extensive tubulointer-
stitial injury, damaged arterioles, and loss of blood flow to
the kidney and hypoxia is a key feature of tubulointersti-
tial disease.1,2 Many studies suggest that hypoxic signaling
plays a critical role in tissue response to injury at the early
and late stages of kidney disease.
A key mediator of hypoxic signaling is hypoxia inducible
factor 1 (HIF-1). HIF-1 is a heterodimer protein complex com-
posed of an alpha and a beta subunit. Under normoxia, mul-
tiple oxygen-dependent catalytic steps degrade HIF-1a sub-
units making the protein inactive. During hypoxia, however,
degradation of HIF-1a is impaired, leading to accumulation
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and coupling of the HIF-1a-1b subunits, which allows for
translocation of the protein to the nucleus and binding to
hypoxia response element of DNA. HIF-1 signaling then facil-
itates transcription of proteins and hormones responsible for
proliferation, angiogenesis, erythropoiesis, and glycolysis.3,4
HIF-1 has been extensively studied in both acute and
chronic kidney diseases.5,6 At early stages of kidney dis-
ease HIF-1 activation has been shown to be protec-
tive against injury, while in chronic states the benefit of
HIF-1 elevation is at best controversial, with some evidence
of increased fibrosis and tissue remodeling.7 Nevertheless,
it has been suggested that HIF-1 induction therapies may
protect against anemia of chronic kidney disease (CKD),
AKI, diabetic nephropathy, and possibly specific chronic
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conditions where HIF-1 levels are altered via transcriptional
and translational pathways.8,9 HIF-1 induction can be either
through stabilization of the protein or gene therapy and
increased expression of the protein.10,11 The effectiveness of
HIF-1 therapy is weighed down by potential risks of over-
activation of HIF-1 systemically. Determining the HIF-1 level
and activity would best assess the effectiveness of HIF-1-
modulating agents.
Quantification of HIF-1 activity is challenging in clinical
studies. Undegraded HIF-1 protein is very unstable and is
primarily found via immunoassays or western blot analy-
sis of kidney tissue.12 In human studies kidney tissue is
only obtained through kidney biopsies, which could be an
invasive approach. In this study we propose an alterna-
tive noninvasive approach to quantify HIF-1a expression
levels from kidney cells collected form urine. Use of urine
cells has previously been suggested as a diagnostic tool for
detection of kidney injury and allograft rejection biomarkers
and methods for mRNA isolation in urine have been previ-
ously developed.13 Using a similar approach, we examined
whether urinary HIF-1a expression can be readily quantified
in urine. We showed a significant difference in urinary HIF-1a
mRNA levels between healthy subjects and CKD patients.
Our findings validate that urinary HIF-1a can be used as




Upon approval from the Institutional Review Board of the
Bernard J. Dunn School of Pharmacy, healthy volunteers as
well as CKD patients (stage III to V) were recruited into the
study. Healthy subjects were recruited at the Bernard J. Dunn
School of Pharmacy in Ashburn, VA, through in-person and
email reach out. Patient recruitment took place at Kidney and
Hypertension Specialists clinics in Manassas, VA. Patients
were initially screened by healthcare providers for eligibility
and a written consent was obtained from patients at their
routine office visits for enrollment into the study. The study
adhered to the Declaration of Helinski. The study inclusion
criteria consisted of age range of 18–95 years old and CKD
stage 3–5 (estimated glomerular filtration rate (eGFR) <60
ml/min/1.73m2) for patients and no active CKD for healthy
subjects based on National Kidney Foundation definitions of
active kidney disease. The exclusion criteria for the study
were as follows: age <18 years, age >95 years, immuno-
compromised, HIV, hepatitis, amyloidosis, sarcoidosis, renal
replacement therapy, autoimmune diseases (with the excep-
tion of diabetes), active infection, shock, valvular heart dis-
eases, active illicit drug use, bladder outlet obstruction,
diabetic ketoacidosis, poisoning sickle cell anemia, active
cancer, Fabry disease, erythropoietin injection or injection in
the past 7 days. All subjects met the inclusion and exclusion
criteria.
eGFR determination
Patients and healthy subjects were asked to provide a one-
time blood sample drawn by a designated nursing staff.
Patient eGFR was determined based on the patient’s serum
creatinine levels pertaining to the date of enrollment at the
clinic. Healthy subject serum creatinine levels were deter-
mined at Valley Health Medical laboratories affiliated with
Shenandoah University School of Pharmacy, Winchester, VA.
Estimated GFRwas calculated using the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) equation based
on serum creatinine levels, age, gender, and race.
Sample storage and transport
Subjects were instructed on proper urine sample collection.
Immediately after collection, samples were either processed
right away for RNA isolation or stored at –20°C at the clinic
then transferred to a –80°C freezer in the laboratory. Appro-
priate insulating packaging, dry ice, and ice packs were used
to transport the frozen samples from the clinics to the labo-
ratory facilities for processing.
Urine sample processing
Fresh 50-ml urine samples were processed as described
below. Frozen samples were thawed at 32°C before pro-
cessing. Samples were spun at 4,200 rpm for 15 min at 4°C
as previously described.14–16 The supernatant was removed
and the pellet was reconstituted with RLT buffer (Qiagen,
Calsbad, CA) plus 10% ethanol. The reconstitutes were cen-
trifuged at 14,000 rpm and the eluates were transferred to
QIAcube device (Qiagen, Calsbad, CA) for RNA isolation.
RNA isolation
RNA isolation was performed in a QIAcube system using to
the Qiagen RNeasy Plus Mini Kit. RNA quality was deter-
mined through purity and concentrationmeasurements using
a Pico100 Picodrop Spectrophotometer.
cDNA synthesis
Total RNA of each sample was converted to cDNA using
the high-capacity reverse transcription kit (Applied Biosys-
tems, Foster City, CA). A total of 10 μl of RNA and 10 μl of
reaction master mix were used in the reverse transcription
experiments.
Real-time reverse-transcription polymerase chain
reaction (RT-PCR)
cDNA samples were amplified using Applied Biosystems
7300 PCR (Applied Biosystems, Calsbad, CA) and the Taq-
Man gene expression assays protocol by Applied Biosys-
tems. Samples were loaded onto 96-well plates in tripli-
cate. For housekeeping gene screening a predesigned panel
of 32 human endogenous control assays (TaqMan Array
96 – Well Plate Endogenous Control, Applied Biosystems)
was utilized. In order to determine gene stability, pairwise
comparisons were made between genes using methods
described by Vandesomple et al. in conjunction with qbase+
(geNorm) software produced by Biogazelle (Belgium).17 To
take into account the effect of varying RNA quality and
amount between samples, the previously described 2−Ct
method was utilized whereby each HIF-1a sample is normal-
ized to its corresponding ACTB values and average of indi-
vidual delta Ct values were used for comparison between
groups.18
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Simultaneous fluorescence in situ hybridization (FISH)
and immunofluorescence
Simultaneous FISH and immunofluorescence was per-
formed following the protocol provided by (Biosearch Tech-
nologies, CA). Urine pellets were washed in 1 ml 1X
phosphate-buffered saline (PBS) two times and fixed with
formaldehyde (3.7% in 1X RNase free PBS) for 10 min. After
the fixation, buffer was removed and washed with 1X PBS
the cells were then permeabilized with 70% ethanol at 4°C
overnight. The following day the ethanol was removed and
the cells were suspended in wash buffer (10% formamide in
2X saline-sodium citrate (SSC)) and incubated for 2–5 min.
After removal of the wash buffer 100 μl of HIF-1a or Kidney
Injury Protein 1 (KIM-1) Stellaris FISH probe (1 μl from 25 μM
stock solution) along with Kidney Specific Protein; Cadherin-
16 (KSP) primary antibody (0.5 μg/ml as final concentration)
was diluted in hybridization buffer (10% formamide in 2X SSC
plus 100 μg/ml of dextran sulfate) and added to the sam-
ples. The samples were then incubated at 37°C overnight.
After the aspiration of hybridization buffer, the samples were
suspended in wash buffer containing 10 μg/ml fluorescently
labeled secondary antibody and incubated for 30 min at
37°C in the dark. One drop of mounting medium containing
1.5 μg/ml of 4’,6-diamidino-2-phenylindole (DAPI) was used
as a DNA counterstain and mounting media. The panel of flu-
orescently labeled FISH probes for HIF-1a and KIM-1 were
custom-designed, each composed of 30–48 oligos (20-bp)
complementary to the coding sequences of these genes.
The cells were imaged using an EVOS inverted fluorescent
microscope and FL auto software at 10–20X magnification
(Life Technologies, Bethesda, MD). Additional imaging stud-
ies were performed using wide-field confocal microscopy.
Images were taken with a Zeiss 510 confocal microscope
using an oil-immersed 40X objective and captured using Zen
9 software.
Data and statistical analyses
Relative quantification of HIF-1a was determined using the
2−Ct method.18 Differences between groups were deter-
mined using Student’s t-test on the delta Ct. mean values.
Correlation analysis of KSP and HIF-1a expression values
was performed using Pearson correlation. All P-values were
two-sided, and P < 0.05 was considered statistically signifi-
cant. Calculations were carried out using the SPSS 22.0 sta-
tistical software (IBM, Armonk, NY).
RESULTS
Characteristics of study population
(Table 1) describes the baseline characteristics of the healthy
(N = 27) and CKD patient (N = 50) populations whose sam-
ples were included in all data analyses. All patients and
healthy subjects met the inclusion criteria and were enrolled
over a period of 2 years. Numbers are broken down based on
age, race, eGFR, and comorbid conditions. Patients were of
CKD stages III–V with mean eGFR of 37 ± 16 in comparison
with healthy subjects with mean eGFR of 97 ± 20. Due to
weighing of age in the eGFR calculation, inclusion of healthy
subjects resulted in a significantly younger age than the CKD
population (32 ± 8 vs. 70 ± 10).
Table 1 Patient Demographics
Healthy (n = 27) CKD (n = 50)
Gender, n (%)
Male 13 (48) 29 (58)
Female 14 (52) 21 (42)
Age (yr) 32 ± 8 70 ± 10
Race (%)
Caucasian 15 (55) 29 (58)
African American 1 (4) 13 (26)
Asian 8(30) 2 (4)
Hispanic — 2 (4)
Other 3 (11) 4 (8)
GFR (ml/min/1.73m2) 97 ± 20 37 ± 16
Comorbidities n (%)
Diabetes — 28 (56)
Hypertension — 45 (90)
Anemia — 19 (38)
Cardiovascular 1 (6) 16 (32)
Respiratory — 5 (10)
CKD, chronic kidney disease; GFR, glomerular filtration rate.
Detection of HIF-1A mRNA in urine
Urinary mRNA levels of HIF-1A were determined by total
RNA isolation from urine pellets and real-time RT-PCR exper-
iments. We examined HIF-1a mRNA isolated from urine sam-
ples obtained from healthy individuals as well CKD patients.
HIF-1a mRNA levels were consistently detectable with aver-
age cycle threshold (Ct) values for HIF-1a ranging from 31.47
± 1.82 and 31.34 ± 1.57 in healthy and CKD urine, respec-
tively. On average, the concentration of urinary RNAwas 8.73
± 3.52 ng/μl, for healthy urine and 10.7 ± 5.36 ng/μl for CKD
urine (N = 45 and 79, respectively).
Identification of the most stable urinary reference genes
A number of reference genes have been reported in pub-
lished studies evaluating gene expression by RT-PCR analy-
sis utilizing urine samples.19 However, we encountered vari-
able results using these previously reported reference genes,
particularly in frozen samples. In order to determine which
reference genes would be the most stable under our exper-
imental conditions we utilized a predesigned panel of 32
human endogenous control assays (TaqMan Array 96 – Well
Plate Endogenous Control, Applied Biosystems). Supple-
mentary Table 1 lists the 32 genes included in triplicate in
this panel. The potential reference genes were first evaluated
in both fresh samples from three healthy individuals. Among
the 32 genes evaluated, only 6 genes (ACTB, B2M, GAPDH,
POLR2A, PES1, and UBC) had consistently detectable Ct
values in fresh urine samples, with a standard deviation of
less than 1.5 Ct units. We then evaluated these six genes in
frozen urine samples from 10 healthy individuals. The sam-
ples were frozen at –80°C for 2–8 days and then processed.
The six genes were also evaluated in a similar manner in
frozen samples from 10 patients with CKD. The average raw
Ct values for the six potential reference genes ranged from
29.13 ± 2.69 to 33.58 ± 4.64 for frozen urine from 10 healthy
subjects, and 30.08 ± 3.02 to 30.79 ± 3.87 cycles for the 10
CKD patients (Figure 1a,b).
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Figure 1 Average raw Ct values from six candidate housekeep-
ing genes and HIF-1a obtained in urine samples. (a) Ct values
for freeze/thaw processed urine from healthy subjects. (b) Ct val-
ues for freeze/thaw processed urine from CKD patients. N = 10
in each group. Boxes represent lower and upper quartiles of cycle
threshold. Whiskers indicate 10th and 90th percentiles. (c) Refer-
ence gene stability in healthy and CKD frozen urine. Stability M
values were obtained using pairwise comparisons of endogenous
control genes for six genes (UBC, PES1, POLR2A, B2M, GAPDH,
ACTB).
To further establish the stability of the six poten-
tial reference genes we used the methods described by
Vandesomple et al. and used in qbase+ (geNorm) software
produced by Biogazelle, with threshold M value of 1.5 as the
upper limit of gene stability.17 Evaluation of the frozen sam-
ples based on pairwise comparison resulted in the exclusion
of PES1, POLR2A, and B2M, leaving only ACTB and GAPDH
with an M value of less than 1.5 in healthy subjects. How-
ever, in the CKD patients the M values of ACTB and B2M
were lower than GAPDH (M values 1.1 vs. 1.7 for GAPDH)
(Figure 1c). As a result, we concluded that among the three
Figure 2 Relative Quantification (RQ) of HIF-1a mRNA expression
in healthy (n = 27) and CKD patient (n = 50) urine samples using
ACTB as the reference gene. (a) RQwas calculated using the 2−Ct
method, bars represent mean fold expression with SEM. The dif-
ference between groups was determined by comparing delta Ct.
Mean values of the CKD vs. healthy controls. (b) Box-and-whisker
representation of delta Ct of urinary HIF-1a in CKD and healthy
subjects. Boxes represent lower and upper quartiles of delta Ct
values. Whiskers indicate 10th and 90th percentiles.
remaining genes, ACTB showed the most consistent expres-
sion stability in frozen samples of both patients and healthy
subjects and would be suitable as the reference gene for rel-
ative quantification of HIF-1a in urine.
Comparison of HIF-1a mRNA in healthy and CKD
subjects
Among the enrolled subjects we were able to successfully
quantify mRNA for 27 healthy adults and 50 patients. To com-
pare HIF-1a expression levels in healthy and CKD patient
populations, we performed real-time RT-PCR quantification
of urine HIF-1a mRNA. Figure 2a,b depicts the difference
in urinary HIF-1a expression between groups. CKD patients
had a 3.91-fold higher expression of HIF-1a mRNA in their
urine with mean RQ value of 1.33 ± 0.29 compared with 0.34
± 0.07 in healthy subjects. Statistical analysis was performed
on the mean delta Ct. Mean values between the CKD and the
control groups and P value was shown to be 0.02.
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Figure 3 Colocalization of HIF-1a mRNA and kidney-specific pro-
tein (cadherin 16) in tubular cells isolated from a CKD patient
urine sample. (a) DAPI stain of the cell nuclei, (b) FISH of HIF-
1a mRNA, (c) immunofluorescence detection of KSP (cadherin 16)
in the same sample snapshot, (d) colocalization of KSP and HIF-
1a mRNA. Images obtained using an inverted fluorescent micro-
scope. (e) Correlation of log KSP and log HIF-1a mRNA fold
expression in urine shed cells using ACTB as endogenous control
(N = 14).
FISH studies of HIF-1a mRNA in urine cells
To further assure that the detected mRNA is representa-
tive of renal levels of HIF-1a, we designed a series of FISH
and immunofluorescence experiments to determine colo-
calization of HIF-1a mRNA with a known renal cadherin
(KSP) as well as a known kidney injury protein, KIM-1. We
designed a panel of fluorescently labeled probes for HIF-1a
and KIM-1, each composed of 30–48 20-bp oligos comple-
mentary to the coding sequences of these genes to detect
the expression of these respective mRNA in patient samples
and controls. Probingwith HIF-1a FISH probe alongwith KSP
immunofluorescent staining produced the anticipated pat-
tern of mRNA and protein localization, including the intense
nuclear and cytoplasmic spots indicative of active transcrip-
tion from mRNA; and protein immunostaining indicative of
kidney-specific tubular cells shredded in urine (Figure 3a–d).
The spots corresponding to mRNAs and protein overlapped
only in cells with morphology similar to those identified
by KIM-1 FISH probes (Figure 4e,f). Cells that did not
have strong fluorescent signals were primarily of transitional
epithelial morphology (Figure 4a–d). Taken together, our data
suggest that the expression of KIM-1 and HIF-1a strongly
correlates with tubular cells as compared with transitional
epithelial cells of bladder and urogenital origins.
Correlation of KSP and HIF-1a urine mRNA
To further establish the degree of correlation of HIF-1a urinary
expression with the kidneymarker KSP, in urine shed cells we
performed real-time RT-PCR analysis of patient urine sam-
ples using KSP and HIF-1a primer-probes. Relative quan-
tification was performed using ACTB as endogenous con-
trol using the previously defined 2−Ct method.18 HIF-1a and
KSP were closely correlatedm with a correlation coefficient r
= 0.58, N = 14 (Figure 3e).
Correlation of HIF-1a mRNA with serum creatinine
We additionally performed a comparison between serum cre-
atinine levels of CKD patients and their corresponding urinary
HIF-1a mRNA values. Figure 5 depicts these results, show-
ing a weak correlation between the two markers (r = 0.26).
DISCUSSION
In this study we demonstrated that HIF-1a mRNA is differen-
tially expressed in healthy vs. CKD patient urine and can be
utilized to extrapolate HIF-1a expression levels in the kidneys
for diagnostic and therapeutic purposes.
Figure 4 FISH imaging of HIF-1a and KIM-1 mRNA in urine isolated cells (a–d) FISH imaging of HIF-1a mRNA (a,c) and KIM-1 mRNA
(b,d) in transitional epithelial cells in a control urine sample (a,b) and patient urine sample (c,d). FISH analysis of HIF-1a mRNA (e) and
KIM-1 (f) colocalized with KSP in tubular kidney cells of a CKD patient sample. (g) 10X view of a patient’s urine isolated cells showing
KIM-1 and KSP colocalization only in renal tubular origin cells. Imaging analysis was performed using widefield confocal microscopy (a–f)
and inverted fluorescent microscopy (g). N = 5–7 in each group.
www.wileyonlinelibrary/cts
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Figure 5 Correlation of HIF-1mRNA with serum creatinine in CKD
patients (r = 0.26, N = 50).
HIF-1a mRNA in human urine
An important observation we made was that HIF-1a mRNA
was consistently quantifiable in urine. One limiting factor in
using urine as a source of mRNA is viability of the samples
for pellet and RNA isolation. Factors such as urine clarity,
concentration of shed cells, as well as freeze–thaw process-
ing of urine affect sample viability. The other limiting factor
is stability of housekeeping genes in frozen urine for normal-
ization. We found that several commonly used housekeeping
genes had variable expression levels in cells shed in urine
in CKD and healthy urine samples. Immediate processing of
the urine samples may in part help both HIF-1a and house-
keeping gene stability. Recently, other urine mRNA isolation
kits have become commercially available that allow for more
rapid mRNA isolation from urine in clinical settings. These
new methodologies will increase yield of urine mRNA anal-
ysis for diagnostic purposes. In our study we conducted a
thorough analysis of a number of housekeeping genes found
in urine pellets of both healthy and CKD patients and found
ACTB to be the most stably expressed housekeeping gene
under frozen conditions for normalization (Figure 2).
Quantification of HIF-1a mRNA in urine accords with high
expression levels of HIF-1 in the kidneys and confirms that
urine is a valuable source for quantifying renal HIF-1a expres-
sion in both healthy and kidney disease conditions. Our
imaging studies confirmed that HIF-1a mRNA is colocal-
ized with kidney markers KSP (Figure 3)20,21 and KIM-1
(Figure 4) in urine shed cells. Although urinary cells are com-
posed of various cell types, including epithelial cells of the
bladder and urethra as well as hematopoietic cells, stud-
ies suggest that HIF-1a is overexpressed in hematopoietic
cells during active cancer or infections.22 Similar observa-
tions have been made in bladder cancer or bladder out-
let obstruction.23,24 In our study population, active cancer,
conditions of bladder, or active infection were excluded.
We specifically showed in our imaging analysis that tran-
sitional epithelial cells of most likely of bladder or urethral
origin do not express HIF-1a as readily. In Figure 4a–f we
show that the FISH signals for both KIM-1 and HIF-1a are
primarily observed in kidney tubular morphology compared
with transitional epithelial morphology. To further support our
hypothesis that the quantified HIF-1a is primarily from the
kidney, in a subgroup of CKD patients we correlated HIF-
1a mRNA relative expression with that of KSP and found
a strong correlation between HIF-1a and KSP mRNA levels
(Figure 3e). These data indicate that the quantified HIF-1a
mRNA levels in urine are most likely of kidney origin.
Increased expression of HIF-1a mRNA in CKD patient
urine
In this study, we showed that HIF-1amRNA expression is sig-
nificantly higher in CKD patients in comparison with healthy
individuals. CKD in our patient population was primarily diag-
nosed secondary to hypertension and diabetes, with the
most common other comorbidities being cardiovascular and
respiratory diseases. It is noteworthy that we enrolled control
individuals with average age of 32 ± 20 years who were sig-
nificantly younger than our patient group age (70± 16 years).
Although this may introduce an unmatched age limitation to
our study, in order to establish a true baseline for urinary HIF-
1a mRNA and to adhere to the definition of eGFR of 90
ml/min/1.73m2, we limited our control group to healthy kid-
neys with no comorbidities or age-related eGFR decline.
Previous studies have shown induction of HIF-1 in models
of acute and chronic kidney injury.6,7,25 It has been shown that
HIF-1 induction produces variable effects at different stages
of kidney injury. Acute kidney injury studies show induction
of HIF-1 may promote adaption to acute hypoxia and pro-
tection of renal tubular tissue.25,26 On the contrary, in mod-
els of chronic kidney injury, prolonged HIF-1 induction has
been shown to induce progression of tubulointerstitial dam-
age and fibrosis.7,27 The progressive physiological effects of
HIF-1 in kidney injury have important diagnostic and thera-
peutic implications. In this study for the first time we showed
that urinary mRNA expression HIF-1a subunit of HIF-1 com-
plex is increased by 3.91-fold in CKD patients of stage III–V
compared with controls. This finding is consistent with previ-
ous animal models of chronic kidney injury and suggests the
potential involvement of HIF-1 in progression of chronic kid-
ney disease. Additionally, transcriptional regulation of HIF-1a
mRNA via molecules such as angiotensin II may greatly alter
HIF-1a expression in the kidneys.28 Additional studies taking
into account the transcription regulation mechanisms of HIF-
1a may better elucidate the specific association of HIF-1 with
different kidney pathologies.
Recently, HIF-1a stabilizing as well as HIF-1 gene induc-
tion therapies have been utilized as therapeutic modalities
for conditions such as anemia of kidney disease and wound
healing.10,11 Given the growth of HIF-1-modulating therapies,
noninvasive measures of HIF-1 expression and activity is
warranted.
The field of nephrology is ever in search of noninvasive
suitable biomarkers of kidney disease.29 Currently, the only
standardized biomarker is serum creatinine, which is non-
specific, has a delayed rise compared with timeline of acute
kidney injury, and is affected by many factors such as age,
muscle mass, diet, and hydration status.
In this study we explored the relationship between HIF-
1a expression and serum creatinine levels and found a weak
correlation between urine HIF-1a mRNA and SrCr (Figure 5).
This finding is not surprising, and further demonstrates that
Clinical and Translational Science
HIF-1: A Biomarker of CKD
Movafagh et al.
7
serum creatinine is a nonspecific indicator of renal function
and does not correlate with specific kidney injury processes
such as hypoxia. More specific urinary biomarkers of chronic
kidney injury are needed to examine a correlation with HIF-1a
mRNA levels.
Among renal pathologies are oxidative stress, inflamma-
tion, structural disease, and fibrosis. A number of molecules
are activated in the kidneys under oxidative stress and
inflammation. Among such are microRNA, which have
recently received a great degree of attention as biomarkers
and studies have shown upregulation and signaling via sev-
eral microRNAs during various types of kidney pathologies.30
MicroRNA knockout models show protection against renal
injury and inhibitors of microRNA show improvement of renal
function.31 Therefore, urinarymicroRNAmRNAmeasurement
has been suggested as a biomarker of kidney disease. In a
similar fashion, HIF-1 upregulation and signaling has been
noted in various kidney pathologies. HIF-1 is especially rel-
evant to oxidative stress and inflammation. As mentioned
before, reactive oxygen species and inflammatory mediators
enhance HIF-1a gene expression.32 Interestingly enough,
various microRNAs also regulate HIF-1a transcription and
vice versa under hypoxia.32,33 Therefore, using HIF-1a mRNA
as a biomarker in the subgroup of ischemia, oxidative
stress, and inflammatory renal injury would be of significant
value. HIF-1a mRNA can provide information regarding the
degree of HIF-1 transcriptional activation under chronic and
acute oxidative and inflammatory injury and can help select
the use of HIF-1 targeted therapies. Additionally, accord-
ing to our findings, HIF-1a mRNA is a suitable noninvasive
biomarker, as it is readily obtained in urine samples, which
clearly validates its advantage over more invasive diagnostic
markers.
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